TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. (2020)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/cid/ciz589
PubMed Identifier: 31425580
Publication URI: http://europepmc.org/abstract/MED/31425580
Type: Journal Article/Review
Volume: 70
Parent Publication: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Issue: 10
ISSN: 1058-4838